Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.
Cats were experimentally inoculated parenterally with the ME49 strain of Toxoplasma gondii to characterize the efficacies of two different dosages of orally administered clindamycin hydrochloride in the treatment of ocular toxoplasmosis. Concentrations of clindamycin hydrochloride at levels previously suggested to be inhibitory to T. gondii replication in vitro were achieved in the serum and aqueous humor but not in the cerebrospinal fluid. Antibiotic therapy, initiated 7 days after inoculation, resulted in no significant difference in the morphometric severity of ocular posterior segment lesions compared with that in the control groups. Treatment appeared to blunt T. gondii-specific immunoglobulin M production but had no significant effect on immunoglobulin G titers. Paradoxically, clindamycin administration was associated with increased morbidity and mortality from hepatitis and interstitial pneumonia, which are characteristic of generalized toxoplasmosis. Serum tumor necrosis factor alpha activity was detected at moderate levels in all groups of cats and correlated with the severity of clinical disease. The results of the study suggest that clindamycin, when administered at this specific time interval following inoculation, does not ameliorate ocular lesions and has a detrimental effect on the clinical course of acute, experimental toxoplasmosis in cats. The factors responsible for and the relevance of this detrimental effect to naturally occurring toxoplasmosis in humans and pet cats were not clear from the study but may relate to an antibiotic-associated decrease in the antitoxoplasmic activity of phagocytic cells responsible for the control of T. gondii.
Davidson
M G
MG
Department of Companion Animal and Special Species Medicine, College of Veterinary Medicine, Raleigh, North Carolina 27606, USA.
Lappin
M R
MR
Rottman
J R
JR
Tompkins
M B
MB
English
R V
RV
Bruce
A T
AT
Jayawickrama
J
J
D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D002415:Cats; D002981:Clindamycin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D014126:Toxoplasmosis, Ocular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D014409:Tumor Necrosis Factor-alpha; D002981:Clindamycin